Ultragenyx Pharmaceutical Inc.
For the period ended Dec 31, 2025. Filed Feb 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 18, 2026
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(575) | $(569) | $(607) |
| Other comprehensive income (loss): | |||
| Foreign currency translation adjustments | 3 | (2) | — |
| Change in unrealized gain (loss) on available-for-sale securities | (1) | — | 8 |
| Other comprehensive income (loss): | 2 | (2) | 8 |
| Total comprehensive loss | $(573) | $(571) | $(599) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.